PM to kick start distribution of PMJAY-MA Yojana Ayushman cards in Gujarat

50 lakh coloured Ayushman cards will be distributed to all the beneficiaries across Gujarat, at their doorstep, by National Health Authority empanelled agencies after doing e-KYC of beneficiaries

Novartis unveils new focused strategy

Transformation to pure-play Innovative Medicines company nears completion

Takara Bio partners with BioeXsen for the distribution of CE-IVD solutions

The reliability of their products, evidenced by their inclusion in the WHO emergency use list, has further improved with the addition of Takara Bio's enzymes.

Panacea Biotec received US FDA communication for Baddi facility

The OAI classification implies that the USFDA expects further corrective actions and may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved

Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries

We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.

Lupin and I'rom signs licensing agreement for Denosumab biosimilar for Japan

Sun Pharma gets OAI from USFDA for Halol facility

The OAI classification implies that the US FDA may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved

India has achieved replacement level fertility: Minister Pawar

Pawar also unveiled the India Family Planning 2030 vision document and launched the Medical Eligibility Criteria (MEC) Wheel Application, E-Module of Family Planning Logistics Management System (FPLMIS) and Digital Archive on Family Planning under the category of Digital Intervention.

Zydus receives final approval from the USFDA for Bisoprolol Fumarate Tablets

Bisoprolol Fumarate Tablets are used to treat high blood pressure.

Glenmark Pharma and SaNOtize announce Peer Reviewed Publication of its Phase 3 Clinical Trials on SaNOtize's Novel Nitric Oxide Nasal Spray

The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.